Magdalena Kegel,  —

Magdalena is a writer with a passion for bridging the gap between the people performing research, and those who want or need to understand it. She writes about medical science and drug discovery. She holds an MS in Pharmaceutical Bioscience and a PhD — spanning the fields of psychiatry, immunology, and neuropharmacology — from Karolinska Institutet in Sweden.

Articles by Magdalena Kegel

Harvard Researchers Explore Cellular Self-destruction as Scleroderma Treatment

Organ fibrosis in scleroderma patients might be reversed with treatments that allow fibrotic cells to self-destruct, Harvard scientists suggest. Their study, “Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis,” appeared in the journal Science Translational Medicine. It demonstrated that the survival–self-destruction balance of fibrosis-producing myofibroblast cells…

Top 10 Scleroderma Stories of 2017

Over the past year, Scleroderma News has brought you news on scleroderma therapeutic developments, clinical trials, research, and events. While we look forward to bringing you more news in 2018, we would like to sum up 2017 by bringing you the Top 10 most-read scleroderma stories, reminding you, our readers,…